Multi-cancer genome profiling (multi-CGP) testing intends to predict the therapeutic efficacy of anticancer medication treatments for eligible patients as part of "precision cancer care." The number of cases in which a new treatment was applied based on multi-CGP testing has been reported to be between 10% and 20% for all patients in Japan. This study aimed to determine the significance of multi-CGP testing in Japan by analyzing clinical data from multi-CGP testing in various solid cancers at our Hospital.

中文翻译：

---

多种癌症基因组分析的临床意义：来自日本一家医院的数据。

多癌症基因组分析（multi-CGP）测试旨在预测抗癌药物治疗对符合条件的患者的治疗效果，作为“精准癌症护理”的一部分。据报道，日本所有患者中基于多重 CGP 测试应用新疗法的病例数在 10% 至 20% 之间。本研究旨在通过分析我院各种实体癌的多重 CGP 检测的临床数据，确定日本多重 CGP 检测的意义。